Skip to main content

Market Overview

Ionis Pharmaceuticals: Q4 Earnings Insights

Share:

 

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share fell 39.10% over the past year to $0.81, which beat the estimate of $0.28.

Revenue of $290,000,000 decreased by 41.30% from the same period last year, which beat the estimate of $274,480,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Feb 24, 2021

Time: 09:00 AM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/952/39530

Price Action

Company's 52-week high was at $64.37

52-week low: $39.32

Price action over last quarter: Up 15.05%

Company Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

 

Related Articles (IONS)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com